Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 4028: Inhibition of IL25 IL17RA improves immune related adverse events of checkpoint inhibitors and reveals antitumor activity

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXizi HuSBShoiab BukhariCTCarly Tymm

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/68e72f4bb6db6435876a87c0https://doi.org/10.1158/1538-7445.am2024-4028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity2024 · 18 citations
  2. 2Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy2024 · 26 citations
  3. 3P015 Interleukin-17 inhibitors rescue therapy in checkpoint inhibitor-associated adverse events: the state of play in 20252026
  4. 4Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors2024 · 4 citations
  5. 5Abstract B039: T-cell–dominated interferon signaling drives immune checkpoint inhibitor–associated pneumonitis and reveals actionable cytokine targets2026